Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing medicines for autoimmune and inflammatory diseases. Its pipeline centers on small-molecule and other precision therapies designed to target disease pathways such as RIPK2 and SLC15A4, with development activities organized around preclinical and clinical programs.

— Odyssey Therapeutics, Inc.
%
Clinical-stage product candidates0% Drug candidates in human trials, including OD-001 and other pipeline assets.
Preclinical discovery programs0% Research-stage programs aimed at identifying and validating new immune targets.
Collaboration revenue100% Revenue from research collaborations, material transfer, option, and license agreements.

Odyssey does not sell approved products today; its near-term counterparties are pharmaceutical collaborators and...

  • Pharmaceutical collaboration partnersprimary

    Companies that enter research, option, or license agreements to access Odyssey's programs and data.

  • Autoimmune disease patientsprimary

    Patients with ulcerative colitis, inflammatory bowel disease, lupus, and related disorders who would use approved therapies.

  • Physicians and specialty clinicssecondary

    Prescribers who would adopt the therapies if clinical data, safety, and convenience support use.

  • Third-party payorssecondary

    Insurers and reimbursement bodies that determine access and utilization for approved medicines.

Odyssey is headquartered in the United States and conducts its research and development activities from that base...

  • •Headquartered in the United States
  • •R&D and clinical operations are U.S.-based
  • •Collaborations may involve non-U.S. counterparties
  • •Future commercialization could expand beyond the U.S.
  • •Regulatory exposure includes U.S. and foreign authorities

Odyssey's strategy is to advance precision medicines for autoimmune and inflammatory diseases, with emphasis on...

01
Advance OD-001 through clinical developmentshort-term

Clinical proof-of-concept is the key step toward later-stage value creation and eventual approval.

02
Broaden the pipeline beyond OD-001medium-term

Multiple programs reduce single-asset dependence and create more shots on goal in immune disease.

03
Maintain collaboration and financing capacityshort-term

Discovery-stage biopharma requires external capital and partnering to fund long development timelines.

Odyssey faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory approval risk, and...

high

Clinical development failure

The company depends on positive efficacy and safety data to move candidates forward.

Scope
OD-001, OD-002 and future pipeline assets
Materiality
high
high

Regulatory approval risk

Even successful trials may not translate into marketing authorization.

Scope
All product candidates
Materiality
high
high

Funding and liquidity dependence

Research and clinical programs require substantial capital before any product revenue exists.

Scope
Corporate operations and pipeline advancement
Materiality
high
medium

Third-party manufacturing reliance

Clinical supply depends on CMOs meeting quality, timing, and scale requirements.

Scope
Drug substance and drug product supply
Materiality
medium
medium

Market acceptance and reimbursement

Approved therapies must win physician, patient, and payor adoption to generate revenue.

Scope
Future commercial products
Materiality
high
medium

Product liability and safety events

Unexpected adverse events can create legal exposure and damage adoption.

Scope
Clinical and future commercial products
Materiality
medium
Collaboration revenue recognition
Can create uneven quarterly revenue
Accrued research and development costs
Affects operating expense timing
Stock-based compensation
Impacts reported losses and dilution analysis
Contingent consideration fair value
Can introduce non-operating volatility

Odyssey Health, Inc.

ODYY · Surgical & Medical Instruments & Apparatus

Ovid Therapeutics Inc.

OVID · Pharmaceutical Preparations

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

vTv Therapeutics Inc.

VTVT · Pharmaceutical Preparations

4D Molecular Therapeutics, Inc.

FDMT · Biological Products, (No Diagnostic Substances)

: 18.7.2026